Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...

Wall Street loves a dominant player, and Eli Lilly (NYSE: LLY) looks unstoppable with its obesity blockbusters printing money ...

As the cost Mounjaro jabs is set to increase by as much as 170 per cent, Jade Kay, who has already spent £2.4k on the drug, ...